Salt Intake and Antiproteinuric Effect of Paricalcitol in Type 2 Diabetes
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 112 participants.
Also called NCT01393808
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 112 participants
- Registry
-
NCT01393808 -
2011-001713-14
-
- Other papers using this trial's data
- Moderate salt restriction with or without paricalcitol in type 2 diabetes and losartan-resistant macroalbuminuria (PROCEED): a randomised, double-blind, placebo-controlled, crossover trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Italy
- Registry status
- Completed
Technical summary
Registry record NCT01393808. Randomized; quadruple masking; primary purpose treatment. Start 2011-09 (registry gives no type); primary completion 2015-07 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Salt Intake and Antiproteinuric Effect of Paricalcitol in Type 2 Diabetes
- Acronym
- PROCEED
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Paricalcitol
- Intervention (Other)
- placebo
- Lead sponsor
- Mario Negri Institute for Pharmacological Research
- Collaborator
- Abbott
Record details
- Record id
cardio:ct-nct01393808- Content hash
3245867dee71c8ac6dfa9680f1f74cb4d7eafe3bd9739ee315637a6f1e9e4ae4